Celldex Therapeutics, Inc. (NASDAQ:CLDX) Forecasted to Earn FY2024 Earnings of ($1.90) Per Share

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Lifesci Capital issued their FY2024 EPS estimates for shares of Celldex Therapeutics in a research note issued on Tuesday, May 7th. Lifesci Capital analyst S. Slutsky expects that the biopharmaceutical company will earn ($1.90) per share for the year. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.85) per share.

Several other equities research analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Finally, Guggenheim boosted their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $66.00.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $41.21 on Thursday. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -14.16 and a beta of 1.60. Celldex Therapeutics has a 1 year low of $22.11 and a 1 year high of $53.18. The firm’s 50 day moving average price is $41.71 and its two-hundred day moving average price is $37.03.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.19. The business had revenue of $4.13 million for the quarter, compared to the consensus estimate of $1.20 million. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%.

Institutional Trading of Celldex Therapeutics

A number of hedge funds have recently modified their holdings of the business. Teacher Retirement System of Texas raised its position in Celldex Therapeutics by 4.8% during the third quarter. Teacher Retirement System of Texas now owns 11,400 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 522 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Celldex Therapeutics by 70.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 805 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of Celldex Therapeutics by 3.6% in the 3rd quarter. New York State Common Retirement Fund now owns 23,780 shares of the biopharmaceutical company’s stock valued at $654,000 after purchasing an additional 821 shares during the period. Swiss National Bank lifted its position in shares of Celldex Therapeutics by 1.0% in the third quarter. Swiss National Bank now owns 88,300 shares of the biopharmaceutical company’s stock worth $2,430,000 after purchasing an additional 900 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in shares of Celldex Therapeutics by 4.6% during the fourth quarter. Fisher Asset Management LLC now owns 21,492 shares of the biopharmaceutical company’s stock worth $852,000 after purchasing an additional 954 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.